Cargando…

Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study

Detalles Bibliográficos
Autores principales:	Queirolo, Paola, Dozin, Beatrice, Morabito, Anna, Banelli, Barbara, Piccioli, Patrizia, Fava, Cristiana, Leo, Claudio, Carosio, Roberta, Laurent, Stefania, Fontana, Vincenzo, Ferrucci, Pier Francesco, Martinoli, Chiara, Cocorocchio, Emilia, Battaglia, Angelo, Ascierto, Paolo A., Capone, Mariaelena, Simeone, Ester, De Galitiis, Federica, Pagani, Elena, Antonini Cappellini, Gian Carlo, Marchetti, Paolo, Guida, Michele, Tommasi, Stefania, Mandalà, Mario, Merelli, Barbara, Quaglino, Pietro, Fava, Paolo, Guidoboni, Massimo, Romani, Massimo, Spagnolo, Francesco, Pistillo, Maria Pia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840259/ https://www.ncbi.nlm.nih.gov/pubmed/29531523 http://dx.doi.org/10.3389/fimmu.2018.00403

Ejemplares similares

Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study
por: Queirolo, Paola, et al.
Publicado: (2017)

Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study
por: Guida, M., et al.
Publicado: (2021)

Vitamin D and the Risk of Non-Melanoma Skin Cancer: A Systematic Literature Review and Meta-Analysis on Behalf of the Italian Melanoma Intergroup
por: Caini, Saverio, et al.
Publicado: (2021)

Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI)
por: Mandalà, Mario, et al.
Publicado: (2020)

The Molecular Landscape of Primary Acral Melanoma: A Multicenter Study of the Italian Melanoma Intergroup (IMI)
por: Elefanti, Lisa, et al.
Publicado: (2021)

No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study
por: Guida, Michele, et al.
Publicado: (2021)

Treatment of Advanced Metastatic Melanoma
por: Quaglino, Pietro, et al.
Publicado: (2021)

Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2017)

Immune Checkpoints and Innovative Therapies in Glioblastoma
por: Romani, Massimo, et al.
Publicado: (2018)

Corrigendum to “Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicenter study of the Italian Melanoma Intergroup (IMI)” [Eur J Canc 137 (2020). Pages 30–39]
por: Mandalà, Mario, et al.
Publicado: (2020)

Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup
por: Bruno, W., et al.
Publicado: (2022)

Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines
por: Boero, Silvia, et al.
Publicado: (2016)

Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines
por: Boero, Silvia, et al.
Publicado: (2015)

Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials
por: Amabile, Simone, et al.
Publicado: (2021)

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
por: Chiarion Sileni, Vanna, et al.
Publicado: (2014)

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
por: Ferrucci, P F, et al.
Publicado: (2015)

Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study
por: Marconcini, Riccardo, et al.
Publicado: (2022)

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Targeting the ERK Signaling Pathway in Melanoma
por: Savoia, Paola, et al.
Publicado: (2019)

Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)
por: Aglietta, Massimo, et al.
Publicado: (2021)

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
por: Queirolo, Paola, et al.
Publicado: (2014)

The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086)
por: Tropea, Saveria, et al.
Publicado: (2022)

Novel Biomarkers and Druggable Targets in Advanced Melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2021)

Editorial: The Evolving Role of Immunotherapy in Non-Melanoma Skin Cancers
por: Guida, Michele, et al.
Publicado: (2022)

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy
por: Chiarion-Sileni, V, et al.
Publicado: (2014)

The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production
por: Laurent, Stefania, et al.
Publicado: (2013)

Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors
por: RAMONDETTA, Alice, et al.
Publicado: (2020)

Environmental Epigenetics: Crossroad between Public Health, Lifestyle, and Cancer Prevention
por: Romani, Massimo, et al.
Publicado: (2015)

Epigenetic Targeting of Glioblastoma
por: Romani, Massimo, et al.
Publicado: (2018)

Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients
por: Carbone, Maria Luigia, et al.
Publicado: (2022)

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
por: Liberini, Virginia, et al.
Publicado: (2021)

Isolation of extracellular vesicles improves the detection of mutant DNA from plasma of metastatic melanoma patients
por: Zocco, Davide, et al.
Publicado: (2020)

Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19
por: Pala, Laura, et al.
Publicado: (2020)

Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: experience from an Italian skin cancer unit
por: Quaglino, Pietro, et al.
Publicado: (2021)

Sunny Holidays before and after Melanoma Diagnosis Are Respectively Associated with Lower Breslow Thickness and Lower Relapse Rates in Italy
por: Gandini, Sara, et al.
Publicado: (2013)

Sentinel Lymph Node Biopsy in Malignant Melanoma of the Head and Neck: A Single Center Experience
por: Rubatto, Marco, et al.
Publicado: (2023)

Melanoma Management during the COVID-19 Pandemic Emergency: A Literature Review and Single-Center Experience
por: Cariti, Caterina, et al.
Publicado: (2021)

Characteristics of Real-World Patients with High-Risk BRAF(V600E/K)-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program
por: Quaglino, Pietro, et al.
Publicado: (2023)

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4g25c8gneeb8pnkmu4p85l6918